Pacer Advisors Inc. Trims Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Key Points

• Pacer Advisors Inc. has **reduced its stake** in Intuitive Surgical by **15.4%**, now owning **38,942 shares** valued at approximately **$19.3 million**.
• Intuitive Surgical's stock has recently opened at **$495.86** with a market cap of **$177.76 billion** and reported a **21.4% increase** in revenue year-over-year, reaching **$2.44 billion** for the latest quarter.
• Insider trading activity includes senior executives reducing their holdings, with **EVP Myriam Curet** selling **4,500 shares** for over **$2.2 million**, reflecting a **92.73% decrease** in her ownership.

Pacer Advisors Inc. trimmed its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 15.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 38,942 shares of the medical equipment provider's stock after selling 7,092 shares during the quarter. Pacer Advisors Inc.'s holdings in Intuitive Surgical were worth $19,287,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in ISRG. Castleark Management LLC lifted its position in shares of Intuitive Surgical by 3.4% during the 4th quarter. Castleark Management LLC now owns 90,469 shares of the medical equipment provider's stock valued at $47,221,000 after acquiring an additional 2,990 shares during the period. Arlington Trust Co LLC lifted its position in shares of Intuitive Surgical by 34.5% during the 1st quarter. Arlington Trust Co LLC now owns 745 shares of the medical equipment provider's stock valued at $369,000 after acquiring an additional 191 shares during the period. Aaron Wealth Advisors LLC lifted its position in shares of Intuitive Surgical by 3.2% during the 1st quarter. Aaron Wealth Advisors LLC now owns 2,509 shares of the medical equipment provider's stock valued at $1,243,000 after acquiring an additional 78 shares during the period. Ewing Morris & Co. Investment Partners Ltd. acquired a new position in shares of Intuitive Surgical during the 4th quarter valued at $454,000. Finally, Whalerock Point Partners LLC acquired a new position in shares of Intuitive Surgical during the 4th quarter valued at $209,000. 83.64% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Intuitive Surgical news, EVP Myriam Curet sold 4,500 shares of the company's stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $492.48, for a total value of $2,216,160.00. Following the completion of the transaction, the executive vice president directly owned 353 shares in the company, valued at $173,845.44. This represents a 92.73% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Jami K. Nachtsheim sold 2,400 shares of the company's stock in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $520.00, for a total value of $1,248,000.00. Following the completion of the transaction, the director owned 6,371 shares of the company's stock, valued at $3,312,920. The trade was a 27.36% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 18,303 shares of company stock valued at $9,180,778. Insiders own 0.70% of the company's stock.

Wall Street Analysts Forecast Growth

ISRG has been the topic of a number of analyst reports. Citigroup restated a "buy" rating and issued a $650.00 target price (up previously from $590.00) on shares of Intuitive Surgical in a report on Thursday, May 22nd. Evercore ISI increased their target price on shares of Intuitive Surgical from $470.00 to $550.00 and gave the stock an "in-line" rating in a research report on Tuesday, July 8th. Robert W. Baird lowered their target price on shares of Intuitive Surgical from $600.00 to $575.00 and set an "outperform" rating on the stock in a research note on Wednesday, April 23rd. Erste Group Bank reissued a "hold" rating on shares of Intuitive Surgical in a report on Wednesday, July 23rd. Finally, Wall Street Zen upgraded shares of Intuitive Surgical from a "hold" rating to a "buy" rating in a report on Saturday. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and fifteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $592.05.

Intuitive Surgical Trading Up 0.9%

NASDAQ:ISRG traded up $4.44 during mid-day trading on Tuesday, reaching $498.39. The company's stock had a trading volume of 1,167,867 shares, compared to its average volume of 1,991,017. Intuitive Surgical, Inc. has a 12-month low of $425.00 and a 12-month high of $616.00. The firm's fifty day moving average price is $528.51 and its two-hundred day moving average price is $534.63. The stock has a market cap of $178.66 billion, a P/E ratio of 69.51, a PEG ratio of 5.20 and a beta of 1.64.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last released its quarterly earnings results on Tuesday, July 22nd. The medical equipment provider reported $2.19 EPS for the quarter, beating the consensus estimate of $1.93 by $0.26. Intuitive Surgical had a net margin of 28.51% and a return on equity of 14.56%. The firm had revenue of $2.44 billion during the quarter, compared to analyst estimates of $2.35 billion. During the same quarter in the prior year, the firm earned $1.78 EPS. The business's revenue for the quarter was up 21.4% compared to the same quarter last year. Analysts predict that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current fiscal year.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.